Latest Announcments
A Major Milestone: JaxBio’s Precision Oncology Study Published
JaxBio’s peer-reviewed study has been published in npj Precision Oncology, reporting a sequencing-free cfDNA methylation microarray assay for lung cancer detection.
In a proof-of-concept study, the assay achieved 93.1% sensitivity at 90.3% specificity, with an AUC of 0.947, and an estimated research workflow cost of approximately $60 per sample.
This is an important step in our mission to make liquid biopsy testing more affordable, scalable, and practical for broader clinical use.
Congratulations to the JaxBio team and all our collaborators.
Read the full article
Why We Do What We Do: Make-A-Wish Guest Noam Visits JaxBio
When Noam was just eight years old, she was diagnosed with cancer. After years of treatment, she recovered.
With a passion for science and hopes of studying medicine or veterinary medicine, her wish was to spend a day experiencing life as a medical researcher.
To make that happen, our entire team came together for her visit. She explored the laboratory, learned about our work and took part in hands-on scientific activities.
We are grateful to have played a small part in making Noam’s wish come true, and we hope this experience is just the first step on her journey toward a future in science.
Noam, we’ll be cheering you on every step of the way.
JaxBio Featured in GenomeWeb: Expanding Access to Affordable Liquid Biopsy
We’re excited to share that JaxBio has been featured in GenomeWeb:
The article takes an in-depth look at our mission to broaden access to DNA methylation-based liquid biopsy testing through a platform designed to be more sensitive, simpler, faster and more affordable.
It highlights our recently published lung cancer proof-of-concept study, which achieved 93.1% sensitivity at 90.3% specificity, with an estimated cost of approximately $60 per sample and a turnaround time of just two to three days.
The feature also explores our ongoing clinical programs, the potential of our technology across lung and hematological cancers, and our plans to bring JaxBio’s tests to patients in the US and Europe.
A big thank you to Justin Petrone for speaking with our CEO, Shahar Zirkin and CSO, Prof. Yuval Ebenstein, and for telling the JaxBio story.
Read the full article:
Affordable, light-based blood tests: The future of lung cancer detection.
Excited to share that our Co-founder & Chief Scientific Officer, Prof. Yuval Ebenstein, has written in ynet about the potential of a simpler, more accessible approach to blood-based lung cancer detection.
The article explores the research behind our sequencing-free technology, which uses light to identify cancer-associated DNA patterns in blood rather than relying on DNA sequencing.
Our goal is to make blood-based lung cancer detection faster and more affordable to access – while continuing to validate the technology through clinical studies.
Read the full article (in Hebrew):https://lnkd.in/dHYbV4ca
Seen on the News
Our work has received significant media recognition, with features in the news.
More About JaxBio
Horizon Europe Cancer Mission Grant
Horizon Europe Cancer Mission Grant The Horizon Europe awarded a Cancer Mission Grant to JaxBio Technologies.The project, named SANGUINE, awarded approximately €8.5M, where €1.7M is
